All In Biotech

Drug Trial Radar · NCT05207670

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

320

Actual

Start

Feb 1, 2022

Primary completion

Oct 1, 2027

Study completion Oct 29, 2027

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma \[NHL\]).

Conditions

  • Non-Hodgkin Lymphoma

Interventions

  • Mosunetuzumab (Cohorts A-C)Drug

    Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only)

  • Mosunetuzumab (Cohorts D-E)Drug

    Participants will receive SC mosunetuzumab for up to 34 cycles

  • TocilizumabDrug

    Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) rate at 24 months after the first study treatment (Cohorts A1, A2, and B)Time frame: From the first study treatment to the first occurrence of disease progression, relapse, or death from any cause, whichever occurs first, as determined by the investigator according to Lugano Criteria 2014 (minimum 2 years)
  2. Objective response rate (ORR), defined as the proportion of participants with a complete metabolic response (CMR) or partial response (PR), as determined by the investigator according to the Lugano Criteria 2014 (Cohorts C, D, and E)Time frame: Cycles 4, 8, 12 and 17 (cycle length=21 days)

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Infirmary Cancer Care

    Mobile, Alabama

  • Alaska Oncology & Hematology, LLC

    Anchorage, Alaska

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • City of Hope

    Duarte, California

  • Rocky Mountain Cancer Centers (Aurora) - USOR

    Aurora, Colorado

  • Medical Oncology Hematology Consultants

    Newark, Delaware

  • SCRI Florida Cancer Specialists South

    Fort Myers, Florida

  • Mayo Clinic Jacksonville - PPDS

    Jacksonville, Florida

  • Cancer Specialists of North Florida - Jacksonville

    Jacksonville, Florida

  • Florida Cancer Specialists - NORTH - SCRI - PPDS

    St. Petersburg, Florida

  • Florida Cancer Specialists - EAST - SCRI - PPDS

    West Palm Beach, Florida

  • Mission Blood and Cancer - MercyOne Cancer Center

    Des Moines, Iowa

  • University of Kansas Medical Center

    Westwood, Kansas

  • Oncology Hematology Care - SCRI

    Zachary, Louisiana

  • American Oncology Partners of Maryland, PA

    Bethesda, Maryland

  • Mayo Clinic - PPDS

    Rochester, Minnesota

  • St. Vincent Frontier Cancer Center

    Billings, Montana

  • Astera Cancer Care East Brunswick

    East Brunswick, New Jersey

  • San Juan Oncology Associates

    Farmington, New Mexico

  • New York Oncology Hematology, P.C.

    Albany, New York

  • New York Cancer & Blood Specialists - New Hyde Park

    New Hyde Park, New York

  • NY Cancer & Blood Specialist

    New York, New York

  • North Shore Hematology Oncology Association PC

    Shirley, New York

  • New York Cancer & Blood Specialists - Bronx

    The Bronx, New York

  • Oncology Hematology Care Inc - Cincinnati - USOR

    Cincinnati, Ohio

  • Oncology Associates of Oregon, P.C.

    Eugene, Oregon

  • Providence Cancer Institute

    Portland, Oregon

  • Kaiser Foundation Hospitals

    Portland, Oregon

  • McGlinn Cancer Institute at Reading Hospital

    West Reading, Pennsylvania

  • Tennessee Oncology Chattanooga

    Chattanooga, Tennessee

  • Tennessee Oncology - Nashville

    Nashville, Tennessee

  • Texas Oncology (Amarillo) - USOR - 1826 Point West Pkwy

    Amarillo, Texas

  • Texas Oncology-Austin Midtown

    Austin, Texas

  • Texas Oncology (Worth) - USOR

    Dallas, Texas

  • Texas Oncology (Tyler) - USOR

    Tyler, Texas

  • Virginia Cancer Specialists - Gainsville

    Gainesville, Virginia

  • Kadlec Clinic Hematology and Oncology

    Kennewick, Washington

  • VA Puget Sound Health Care System - NAVREF - PPDS

    Seattle, Washington

  • MultiCare Deaconess Cancer and Blood Specialty Center

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.